J.P. Morgan analyst Brian Cheng has maintained their bullish stance on PTCT stock, giving a Buy rating on November 6.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Brian Cheng’s rating is based on several compelling factors that highlight the potential of PTC Therapeutics. The launch of Sephience has been notably strong, with rapid penetration into Centers of Excellence (COEs), where approximately 75% have already prescribed the treatment. This quick uptake is supported by a well-established target market and favorable coverage policies from major payers, covering over 80 million lives. The company’s strategic approach to pricing and market entry, focusing on regions with favorable pricing corridors, further strengthens its position.
Additionally, the management’s emphasis on maintaining a narrow pricing corridor and the strategic sequencing of launches across different geographies, such as the US, EU, and Japan, are expected to optimize revenue potential. The expected moderation of the gross-to-net ratio as government coverage increases, along with the differentiated profile of Sephience compared to existing treatments, positions PTC Therapeutics for continued success. These factors collectively contribute to Brian Cheng’s Buy rating for PTCT, reflecting confidence in the company’s growth trajectory and market strategy.
In another report released on November 6, TR | OpenAI – 4o also upgraded the stock to a Buy with a $80.00 price target.
Based on the recent corporate insider activity of 68 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PTCT in relation to earlier this year.